Stocks News Update: Rennova Health, Inc. (NASDAQ:RNVA), Transgenomic Inc. (NASDAQ:TBIO)

Rennova Health, Inc. (NASDAQ:RNVA)

The company announced its last quarter financial performance results on 11/14/2016. Rennova Health, Inc. (NASDAQ:RNVA) belongs to Medical sector that declined -11.5% in value when last trading session closed at $0.1. The company has a market capitalization of $5.62 Million. The company’s stock has a Return on Assets (ROA) of 0 percent, a Return on Equity (ROE) of 0 percent and Return on Investment (ROI) of -334.8 percent. The company reached its 52-Week high of $1.16 on Jun 8, 2016 and 52-Week low of $0.08 on Jan 11, 2017.

Earnings per share (ttm) for Rennova Health, Inc. (NASDAQ:RNVA) according to Finviz Data is $1.11.

The 1 analysts offering 12-month price forecasts for Rennova Health Inc have a median target of 18.50, with a high estimate of 18.50 and a low estimate of 18.50. The median estimate represents a +18,400.00% increase from the last price of 0.10.

Financial History:

Following Earnings result, share price were DOWN 3 times out of last 3 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 22% percent of times. It has met expectations  0 times and missed earnings  2  times.

The consensus recommendation for Rennova Health, Inc. (NASDAQ:RNVA) is 3. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 3. In comparison, the consensus recommendation 60 days ago was at 3, and 90 days ago was at 3 respectively.

Company Profile:

Rennova Health, Inc. provides diagnostics and supportive software solutions to healthcare providers. The Company’s solutions include diagnostic solutions, revenue cycle management, healthcare software solutions, financial services, diagnostic laboratory testing and analytics for precision medicine, electronic health records and other software services. Rennova Health, Inc., formerly known as CollabRx, Inc., is headquartered in West Palm Beach, Florida.

Transgenomic Inc. (NASDAQ:TBIO):

Transgenomic Inc. (NASDAQ:TBIO) belongs to Medical sector closed its last session with a gain of 287.01 percent and closed its previous trading session at $1.12. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-0.5. The company has the Market capitalization of $28.8 Million. The company’s stock has a Return on Assets (ROA) of 0 percent, a Return on Equity (ROE) of 0 percent and Return on Investment (ROI) of 176.8 percent. The company reached its 52-Week high of $1.27 on Jan 12, 2017 and 52-Week low of $0.15 on Nov 8, 2016.

This company was Downgrade by RBC Capital Mkts on 31-Oct-02 to Underperform.

The 1 analysts offering 12-month price forecasts for Transgenomic Inc have a median target of 7.00, with a high estimate of 7.00 and a low estimate of 7.00. The median estimate represents a +525.00% increase from the last price of 1.12.

Financial History:

Following Earnings result, share price were UP 3 times out of last 6 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 33% percent of times. It has met expectations  1 times and missed earnings  4  times.

Company Profile:

Transgenomic provides innovative research tools to the genomics segment of the life sciences industry. These tools enable researchers to discover and understand variations in the human genetic code. The company believes its WAVE System, which incorporates its proprietary DNASep separation column and associated software, chemical reagents and other consumable items, will become a leading tool to analyze genetic mutations. The WAVE System allows researchers to analyze both known and unknown genetic mutations faster, with more accuracy and at a lower cost than other techniques.